# Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease

> **NCT00141960** · PHASE2,PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 480 (—)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** Famotidine

## Key facts

- **NCT ID:** NCT00141960
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 480 (—)
- **Last updated:** 2011-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141960, "Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00141960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*